순환종양세포 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Circulating Tumor Cell Market

The future of the global circulating tumor cell market looks promising with opportunities in the hospital & clinic, diagnostic center, and research & academic institute markets. The global circulating tumor cell market is expected to reach an estimated $49 billion by 2035 from $18 billion in 2027 with a CAGR of 13.9% from 2027 to 2035. The major drivers for this market are he increasing demand for early cancer detection, the rising adoption of liquid biopsy techniques, and the growing focus on personalized cancer treatments.

• Lucintel forecasts that, within the product category, kits & reagents is expected to witness the highest growth over the forecast period due to kits and reagents are consumed repeatedly and cost efficiency is prioritized.
• Within the end use category, research & academic institutes is expected to witness the highest growth over the forecast period due to oncology research activities are increasingly undertaken by academic institutions.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to financing for oncology research and advances in liquid biopsies is available.

Emerging Trends in Circulating Tumor Cell Market

Tumour cell technology has predominantly been used in basic research and is expected to transition towards clinical use around 2025 to 2027. During this period, Lucintel anticipates that the major market drivers will be liquid biopsies, cancer treatment evaluation, and biomarker discovery. Improved sensitivity of assays, better reimbursement, and the preference of healthcare professionals to use less invasive cancer biopsy methods will be the major drivers.

• Clinical Evidence: In 2025, additional studies demonstrated that quantification of circulating tumour cells in the blood is predictive of disease prognosis, and correlated with therapy response. The FDA cleared use of the Cell Search technology for the diagnosis of metastatic breast cancer, prostate cancer and colorectal cancer. In the next 3 to 5 years, further clinically relevant data will facilitate the incorporation of this technology into routine oncology practice.
• Analytical Limitations: Single cell/molecular technologies continue to improve, and in the next few years, multiple studies will use a combination of physical and molecular technologies to capture cancer cells to improve the sensitivity of tumour cell detection.
• Multi-omics Integration: In 2025, studies plan to integrate circulating tumour DNA, RNA, and protein signals, along with circulating tumour cells. This allows researchers to create more comprehensive biomarkers, and should help researchers better stratify patients and select appropriate therapies.
• Automation and Standardization of Workflows: Continuous efforts toward the automation of laboratory assays and standardization of laboratory workflows should improve the consistency of diagnostic tests and increase the throughput of laboratory assays. Furthermore, the automated nature of these platforms and workflows should reduce the personnel requirements of a laboratory. The diagnostic industry should benefit from improved workflows and consistency during the 2025-2027 timeframe.
• Specialization: From 2020 to 2025, the focus of diagnostic companies should be on establishing evidence of the clinical utility of their diagnostics in order to gain reimbursement. The oncology market should continue to provide opportunities to meet this goal.

Evidence that supports the clinical utility of a diagnostic test for a specific condition should enable the widespread adoption of circulating tumour cell diagnostics. Evidence may come from collaborations among diagnostic, pharmaceutical, and clinical researchers.

Recent Developments in the Circulating Tumor Cell Market

The market for circulating tumour cells (CTCs) is shifting from research to clinical use, specifically for selecting cancer treatments and monitoring tumors over time. The most significant advances are expected to occur between 2020 and 2025. Lucintel anticipates that in the subsequent years, the market will continue to progress as the automation and reimbursement of CTC tests becomes a reality.

• Strategic Partnership: The standardization of CTC tests, as evidenced by the partnerships between Menarini and several major pathology laboratories in March 2025, will lead to wider clinical use and longer-term contracts.
• Technology Launches: A considerable increase in the automation and throughput of CTC tests, as announced by Recite in June 2025, will favourable impact the economics of CTC tests and increase access to the technology beyond major medical centres.
• Clinical Contracts: The selection of CTC tests by major pharmaceutical companies to monitor the effectiveness of cancer therapies, as announced by Epic Sciences in September 2025, will lead to improved acceptance of CTC tests.
• Production Expansion: The continuous increase in the production of CTC tests, as announced by Menarini in January 2026, will improve the overall supply of CTC tests.
• Government Approvals: Regulatory bodies have been more amenable to liquid biopsy dossiers in 2026, including dossiers supporting CTC endpoints in oncology. Continued progress will likely lead to clarification of CMS approval processes for liquid biopsy and reduced risk for sponsors, facilitating reimbursement negotiations.

The CTC analyser has transitioned to a service model from a capital instrument model. Sponsors of clinical trials have recently been the primary market for CTC testing. In the hospital setting, the adoption and reimbursement of CTC testing is variable based on the cancer type, and the evidence supporting the test. Laboratories that incorporate automation and centralization and offer multiple assays will increase profitability. In the coming years, vendors will be successful if they integrate CTC testing to aid in the decision-making process for cancer treatment rather than providing CTC counts in isolation. Offering such integration will provide a sustainable competitive edge. Novelty of the technology will be of lesser importance. In the coming years, the technology will primarily be used to support the development of new oncology drugs.

Strategic Growth Opportunities in the Circulating Tumor Cell Market

The market for products and services cantered on circulating tumour cells (CTCs) is transitioning from early-stage research to clinical applications. From 2024 to 2026, anticipate first commercial sales for use cases including precision cancer therapy and monitoring therapy resistance. Additionally, expect sales from laboratory testing performed at remote patient locations. In the medium to long-term, the market is expected to expand as the body of supporting clinical evidence grows and pharmaceutical companies use CTC assays to select cancer patients for therapeutic management.

• Therapy Response Monitoring: Pharmaceutical companies will also be interested in CTC analysis as they evaluate the efficacy of their cancer therapies. Positive evidence from therapy monitoring studies has the potential to catalyze further interest from the pharmaceutical industry. Sponsored evidence is likely to increase, particularly if studies demonstrate a positive impact on patient management.
• Clinical Trials: The results of CTC analysis can also aid in the enrolment and stratification of clinical studies. Furthermore, CTC analysis may aid in the understanding of mechanisms of therapy resistance.
• Single-cell Molecular Profiling: As of June 2025, single-cell assays primarily analysed less than ten cells from patient samples. However, the growth of this technique will allow for the characterization of rare cells, and assist oncologists in developing personalized therapies and understanding mechanistically why some cancers become drug resistant.
• Decentralized Oncology Testing: The development of hand-held cancer tests, along with improvements in other non-communicable disease diagnostic tests, will lead to an increased demand for rapid, point-of-care diagnostics in the next five to seven years.
• Companion Diagnostics: Companies focusing on circulating tumour cells (CTCs) will have the opportunity to develop other companion diagnostics in conjunction with pharmaceutical companies. In the long-term, liquid biopsies will be commercially competitive against traditional tissue biopsies.

The largest challenge for the broad market adoption of CTC assays is reimbursement. In oncology, standardization of CTC assays will allow the broad adoption of CTC testing. CTC assays will allow researchers to understand the biology of tumors and their metastasis. Focused efforts to establish assay utility in specific cancers will yield the best market opportunity. Long term, CTC companies will thrive if they establish a repeatable, reimbursement-protected customer base for advanced molecular testing for oncology.

Circulating Tumor Cell Market Drivers and Challenges

The increasing incidence of cancer drives the need for advanced cancer monitoring. Along with this, the desired monitoring should be less invasive for the patient and easier for the practitioner. Newer technologies in the field of circulating tumour cell (CTC) analysis enable the capture of cancer cells in the blood and facilitate decision-making in-patient management. Limitations in CTC test reimbursement and adoption are expected to ease with improvements in the standardization of the tests and CTC assay automation.

The factors responsible for driving this market include:

• Rising Customer Interest: With the advantages of CTC technology, hospitals and laboratories are investing in CTC analysis to aid in the prognosis and management of cancer patients. The American Cancer Society's report (Jan 2025) projected approximately 2.04 million cancer cases for 2025 in the U.S. With these increasing numbers, hospitals and research facilities are expected to intensify efforts to develop more effective cancer management strategies, including the use of CTC testing.
• Technology: Technology has improved in microfluidics, imaging, artificial intelligence, and other areas related to molecular characterizations. Single cell sequencing has improved the analysis of CTCs. In 2025, research platforms had the ability to simultaneously analyse cellular information and mutations relating to cancer and other targets of treatment. Continued integration of automation and instruments would eliminate the variability between laboratory personnel and improve the overall efficiency of a laboratory. It is anticipated that in the next 3 to 5 years, advanced platforms would enable the real time assessment of cancer cells and their response to various therapies.
• Regulatory: Various regulatory agencies have introduced or modified policies relating to personalized medicine, companion diagnostics and laboratory developed tests. In 2025, Europe and other regions enforced the EU In-vitro diagnostic (EU IVD) directive. The directive increased the burden on diagnostic laboratories to validate their tests, but brought regulatory certainty and confidence to the diagnostic industry. The Enhanced policies would facilitate the establishment of standard tests by diagnostic companies and encourage collaboration between the diagnostic and pharmaceutical industries.
• Product Innovation: Currently, manufacturers are combining multiple downstream assays into a single workflow. For example, they are integrating cellular assays for enrichment, enumeration and imaging with molecular assays and digital readouts. Our sponsored research in September 2025 showed that the field of oncology is focusing on the use of multiplexed tumour markers, as opposed to relying on absolute numbers of circulating tumour cells. The usage of multimarket panels allows for classification of tumour subtypes and selection of personalized therapies. As the volume and complexity of clinical assays continue to increase, innovative products need to be developed to address the challenge of performing multiple clinical assays using limited volumes of patient blood. There is significant potential for products that integrate various assays for clinical research, such as immunotherapy, and assessment of minimal residual disease. During the next three to five years, we expect our R&D initiatives to lead to enhancement of our product line and strengthening of our position in the clinical market.
• Manufacturing Advancements: We continuously enhance our assay automation and manufacture reagents stabilizers to reduce the time and cost of performing clinical assays. In March 2026, several manufacturers launched innovative, sample-to-answer, automated systems to enable healthcare professionals in general and oncology laboratories to perform CLIA-certified testing. These systems not only reduce turnaround times, but also improve the cost effectiveness of performing clinical assays. We expect the same trends to continue for other clinical assays. Over the next three to five years, we expect testing to be widely available at major oncology centres and other hospitals.

The challenges facing this market include:

• Insufficient Standardization of Clinical Practices: There remains variation in methods for collection and enrichment of circulating tumour cells, and in reporting standards and molecular markers. As of February 2025, there continued to be a lack of interchangeability of assays for various tumour types, particularly for tumour types with low or variable cellular shedding. This variability impedes development of standardized clinical practice and multi-centre studies, as well as poses challenges in determining reimbursement and assessing therapeutic outcome. Low cellular tumour loads can give rise to false-negative results. Epithelial cell adhesion molecule (EpCAM) dependent methods can fail to detect cells that have undergone epithelial-mesenchymal transition. Without improved standards and practices, challenges in the adoption of circulating tumour cell assays will continue for the foreseeable future.
• Economic Constraints and Reimbursement Challenges: Compensation for CTC assays are not well established. The cost of the instruments and the specialized personnel required for its performance and interpretation remains a barrier. As of July 2025, several health care systems performed assessment of advanced liquid biopsies, and in the absence of compelling data showing improvements in survival and Diagnostic challenges associated with advanced liquid biopsies will continue for the foreseeable future.
• Biology of Circulating Tumour Cells and Sample Handling: Circulating tumour cells are rare, and if captured, challenging to characterize due to biological variability. 2025 Industry Reports on Liquid Biopsies noted that there are several reasons for variable results in a liquid biopsy, including, but not limited to, delays and variations in temperature during sample processing and transport, cellular loss, and heterogenicity among metastatic tumour cells. A sample may not represent all of the metastatic sites, and cells captured in the sample may not be representative of the metastatic cellular population. These uncertainties negatively impact the confidence level of the practitioner. It is expected that during the next 5 years, advances in sample quality and concurrent improvements in multiple assay methodologies will help facilitate the transformation of laboratory diagnostics to the clinical setting.

It is generally anticipated that the global market for circulating tumour cell technology will experience robust growth. The global oncology market is rapidly expanding with advances in personalized medicine. Additionally, liquid biopsy technologies are gaining traction. There are numerous advantages of integrating automated, multiple molecular platforms. Although there are many opportunities and advances in the field, there are equally as many challenges, including cost-prohibitive prices and lack of reimbursement. Many market observers agree that advances in this field are likely to occur in high-level oncology research, rather than in routine clinical care, during the next 5 years.

List of Circulating Tumor Cell Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies circulating tumor cell market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the circulating tumor cell market companies profiled in this report include-

• AVIVA Biosciences
• Greiner Bio-One International GmbH
• IVDiagnostics
• BioCEP Ltd
• Fluxion Biosciences
• Precision for Medicine
• Miltenyi Biotec GmbH
• Ikonisys
• Bio-Techne Corporation
• Qiagen NV

Circulating Tumor Cell Market by Segment

The study includes a forecast for the global circulating tumor cell market by product, specimen, application, end use, and region.

Circulating Tumor Cell Market by Product [Value ($B) from 2019 to 2035]:

• Kits & Reagents
• Blood Collection Tubes
• Devices

Circulating Tumor Cell Market by Specimen [Value ($B) from 2019 to 2035]:

• Blood
• Bone Marrow
• Others

Circulating Tumor Cell Market by Application [Value ($B) from 2019 to 2035]:

• Research, Clinical
• Drug/Therapy Development

Circulating Tumor Cell Market by End Use [Value ($B) from 2019 to 2035]:

• Hospital & Clinics
• Diagnostic Centers
• Research & Academic Institutes

Circulating Tumor Cell Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Circulating Tumor Cell Market

The market for products and services based on circulating tumor cells (CTCs) is transitioning from focusing on their use in prognostic testing to their use in choosing the best cancer treatment and in monitoring cancer treatment. Over the next several years, there is expected to be growth in funding and research collaborations in the area of liquid biopsies and automation of the clinical and laboratory testing of CTCs. According to Lucintel, in the near and medium term, the market will be determined by the level of consistency and reliability, reimbursement, and integration with molecular diagnostic tests.

• United States: Various diagnostic companies and several federal agencies have set up or are setting up programs to establish evidence-based standards for liquid biopsy tests. In the United States, the CTC field still largely depends on the Menarini (CellSearch) platform. In 2025, the U.S. FDA launched the Project Catalyst initiative (with 12 oncology partnering diagnostics) to expedite the review of oncology diagnostic tests. The initiative should positively impact the reimbursement and adoption of CTC tests by U.S. hospitals.
• China: Investment in biotechnology, particularly in the field of translational medicine, fosters the development of CTC tests. In 2025, the Chinese NMPA (formerly CDE) granted approval to 15 innovative in-vitro diagnostic devices, several of which are in the field of oncology. Chinese CTC tests can be expected to gain wider market acceptance in China.
• Germany: Decentralized liquid-biopsy tests are gaining popularity among German cancer centers and diagnostics companies, with CTC tests becoming more prevalent in the context of precision oncology. Funding from the German Federal Ministry of Education and Research in February 2025 (€40 million) for translational cancer research further demonstrates Germany's commitment to funding cancer-related research. Historically, publicly funded research has facilitated the transition of CTC assays from research to clinical practice.
• India: Affordable CTC assays are being developed to test breast, lung and colorectal cancers. In April 2025, the Department of Biotechnology of India selected 20 projects in cancer research as part of its translational research programs. Cheaper diagnostic and research tools in India have allowed companies to develop assays and instruments for CTC enumeration.
• Japan: Several research studies on various cancers (e.g. gastric, pancreatic, lung, colon and prostate) integrate CTC testing within the framework of liquid biopsies. Japan's commitment to research, combined with an aging population and a growing number of cases of several cancers, will likely allow for the adoption of CTC testing in clinical practice.

Features of the Global Circulating Tumor Cell Market

• Market Size Estimates: circulating tumor cell market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: circulating tumor cell market size by various segments, such as by product, specimen, application, end use, and region in terms of value ($B).
• Regional Analysis: circulating tumor cell market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different products, specimen, applications, end uses, and regions for the circulating tumor cell market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the circulating tumor cell market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the circulating tumor cell market by product (kits & reagents, blood collection tubes, and devices), specimen (blood, bone marrow, and others), application (research, clinical and drug/therapy development), end use (hospital & clinics, diagnostic centers, and research & academic institutes), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Circulating Tumor Cell Market by Product

• 4.1 Overview
• 4.2 Attractiveness Analysis by Product
• 4.3 Kits & Reagents : Trends and Forecast 2019 to 2035
• 4.4 Blood Collection Tubes : Trends and Forecast 2019 to 2035
• 4.5 Devices : Trends and Forecast 2019 to 2035

5. Global Circulating Tumor Cell Market by Specimen

• 5.1 Overview
• 5.2 Attractiveness Analysis by Specimen
• 5.3 Blood : Trends and Forecast 2019 to 2035
• 5.4 Bone Marrow : Trends and Forecast 2019 to 2035
• 5.5 Others : Trends and Forecast 2019 to 2035

6. Global Circulating Tumor Cell Market by Application

• 6.1 Overview
• 6.2 Attractiveness Analysis by Application
• 6.3 Research, Clinical : Trends and Forecast 2019 to 2035
• 6.4 Drug/Therapy Development : Trends and Forecast 2019 to 2035

7. Global Circulating Tumor Cell Market by End Use

• 7.1 Overview
• 7.2 Attractiveness Analysis by End Use
• 7.3 Hospital & Clinics : Trends and Forecast 2019 to 2035
• 7.4 Diagnostic Centers : Trends and Forecast 2019 to 2035
• 7.5 Research & Academic Institutes : Trends and Forecast 2019 to 2035

8. Regional Analysis

• 8.1 Overview
• 8.2 Global Circulating Tumor Cell Market by Region

9. North American Circulating Tumor Cell Market

• 9.1 Overview
• 9.2 North American Circulating Tumor Cell Market by Product
• 9.3 North American Circulating Tumor Cell Market by End Use
• 9.4 The United States Circulating Tumor Cell Market
• 9.5 Canadian Circulating Tumor Cell Market
• 9.6 Mexican Circulating Tumor Cell Market

10. European Circulating Tumor Cell Market

• 10.1 Overview
• 10.2 European Circulating Tumor Cell Market by Product
• 10.3 European Circulating Tumor Cell Market by End Use
• 10.4 German Circulating Tumor Cell Market
• 10.5 French Circulating Tumor Cell Market
• 10.6 Italian Circulating Tumor Cell Market
• 10.7 Spanish Circulating Tumor Cell Market
• 10.8 The United Kingdom Circulating Tumor Cell Market

11. APAC Circulating Tumor Cell Market

• 11.1 Overview
• 11.2 APAC Circulating Tumor Cell Market by Product
• 11.3 APAC Circulating Tumor Cell Market by End Use
• 11.4 Chinese Circulating Tumor Cell Market
• 11.5 Indian Circulating Tumor Cell Market
• 11.6 Japanese Circulating Tumor Cell Market
• 11.7 South Korean Circulating Tumor Cell Market
• 11.8 Indonesian Circulating Tumor Cell Market

12. ROW Circulating Tumor Cell Market

• 12.1 Overview
• 12.2 ROW Circulating Tumor Cell Market by Product
• 12.3 ROW Circulating Tumor Cell Market by End Use
• 12.4 Middle Eastern Circulating Tumor Cell Market
• 12.5 South American Circulating Tumor Cell Market
• 12.6 African Circulating Tumor Cell Market

13. Competitor Analysis

• 13.1 Product Portfolio Analysis
• 13.2 Operational Integration
• 13.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

• 14.1 Value Chain Analysis
• 14.2 Growth Opportunity Analysis
  • 14.2.1 Growth Opportunity by Product
  • 14.2.2 Growth Opportunity by Specimen
  • 14.2.3 Growth Opportunity by Application
  • 14.2.4 Growth Opportunity by End Use
• 14.3 Emerging Trends in the Global Circulating Tumor Cell Market
• 14.4 Strategic Analysis
  • 14.4.1 New Product Development
  • 14.4.2 Certification and Licensing
  • 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

• 15.1 Competitive Analysis Overview
• 15.2 AVIVA Biosciences
  • Company Overview
  • Circulating Tumor Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.3 Greiner Bio-One International GmbH
  • Company Overview
  • Circulating Tumor Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.4 IVDiagnostics
  • Company Overview
  • Circulating Tumor Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.5 BioCEP Ltd
  • Company Overview
  • Circulating Tumor Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.6 Fluxion Biosciences
  • Company Overview
  • Circulating Tumor Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.7 Precision for Medicine
  • Company Overview
  • Circulating Tumor Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.8 Miltenyi Biotec GmbH
  • Company Overview
  • Circulating Tumor Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.9 Ikonisys
  • Company Overview
  • Circulating Tumor Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.10 Bio-Techne Corporation
  • Company Overview
  • Circulating Tumor Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.11 Qiagen NV.
  • Company Overview
  • Circulating Tumor Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

16. Appendix

• 16.1 List of Figures
• 16.2 List of Tables
• 16.3 Research Methodology
• 16.4 Disclaimer
• 16.5 Copyright
• 16.6 Abbreviations and Technical Units
• 16.7 About Us
• 16.8 Contact Us